Standout Papers
- A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. (1994)
- A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. (1994)
Citation Impact
Citing Papers
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
The IASP classification of chronic pain for ICD-11: chronic primary pain
2018 Standout
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
2009
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
2014
Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines
2013
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study
2011
Risk factors for functional limitations in patients with long‐standing ankylosing spondylitis
2005
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
2004
Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?
2005
High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study
2013
A six‐month randomized, controlled, double‐blind, dose‐response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis
2002
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
2005 StandoutNobel
Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies
2014 Standout
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system
2003
Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)
2005
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems
2004
Role of Transforming Growth Factor β in Human Disease
2000 Standout
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis
2004
Use of a numerical rating scale as an answer modality in ankylosing spondylitis–specific questionnaires
2002
The bath ankylosing spondylitis radiology index (BASRI): A new, validated approach to disease assessment
1998
TGF-β signaling in tumor suppression and cancer progression
2001 Standout
Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases
2011
Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response
2007
Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions
2007
Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo‐controlled trial
2006
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data
2005
Improvement of lipid profile is accompanied by atheroprotective alterations in high‐density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis
2009
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
2008
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial
2006
Is disease severity in ankylosing spondylitis genetically determined?
2001
Five Years of GWAS Discovery
2012 Standout
Six‐month results of a double‐blind, placebo‐controlled trial of etanercept treatment in patients with active ankylosing spondylitis
2003
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab
2007
Combined spa–exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial
2001
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Patient-assessed health in ankylosing spondylitis: a structured review
2005
Osteoporosis: now and the future
2011 Standout
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
2006
Alopecia areata update
2010 Standout
Assessment of enthesitis in ankylosing spondylitis
2003
Role of the Microbiota in Immunity and Inflammation
2014 Standout
Randomized double‐blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy
2002
Binding of pRB to the PHD Protein RBP2 Promotes Cellular Differentiation
2005 StandoutNobel
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
2015 Standout
WNT signaling in bone homeostasis and disease: from human mutations to treatments
2013 Standout
Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel
2003
THE RISKS OF SYSTEMIC CORTICOSTEROID USE
1998
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
2011 Standout
Psoriasis
2015 Standout
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two
2008
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
2009 Standout
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
2004
Six months open label trial of leflunomide in active ankylosing spondylitis
2004
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis
2005
Ankylosing spondylitis
2007 Standout
The Effect of Infliximab and Timing of Vaccination on the Humoral Response to Influenza Vaccination in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
2009
Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients
2001
Psoriatic arthritis assessment tools in clinical trials
2005
Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study
2004
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
2003
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
2002 Standout
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept
2005
Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis
2009
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Determinants of hyperkyphosis in patients with ankylosing spondylitis
2005
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- antibody infliximab
2007
Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis
2004
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation
2007
Mechanisms of angiogenesis
1997 StandoutNature
The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R))
2004
Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab
2000
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
2010 Standout
Suppression of bone formation by osteoclastic expression of semaphorin 4D
2011 Standout
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty‐two–week open‐label trial
2006
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study
2011
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab
2005
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks
2005
Mechanisms of angiogenesis and arteriogenesis
2000 Standout
Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years
2005
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
2004
Cytokines in the pathogenesis of rheumatoid arthritis
2007 Standout
Telomerase Activity in Human Leukemic Cell Lines Is Inhibited by Antisense Pentadecadeoxynucleotides Targeted against c-myc mRNA
1997
Quality criteria were proposed for measurement properties of health status questionnaires
2006 Standout
One‐year open‐label trial of thalidomide in ankylosing spondylitis
2002
ANKYLOSING SPONDYLITIS
1998
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial
2003
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis
2004
Pain: a review of three commonly used pain rating scales
2005 Standout
Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis
2009
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis
2012 Standout
Role of NOD2 variants in spondylarthritis
2002
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
2000 Standout
Susceptibility to ankylosing spondylitis in twins the role of genes, HLA, and the environment
1997
Impaired Peripheral Th1 CD4+ T Cell Response to Escherichia coli Proteins in Patients with Crohn’s Disease and Ankylosing Spondylitis
2011
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab
2005
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
2009 Standout
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial
2005
Dickkopf-1 is a master regulator of joint remodeling
2007
Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double‐blind, placebo‐controlled magnetic resonance imaging study
2006
Assessments in ankylosing spondylitis
2006
Inferences, questions and possibilities in Toll-like receptor signalling
2004 StandoutNatureNobel
What is the most appropriate radiologic scoring method for ankylosing spondylitis?
2004
Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease
2004 Standout
Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity
2014
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
2005
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Assessment of patients with psoriatic arthritis: A review of currently available measures
2004
Aortic root disease and valve disease associated with ankylosing spondylitis
1998
The role of inflammation in depression: from evolutionary imperative to modern treatment target
2015 Standout
Transforming growth factor-β: pleiotropic role in the regulation of hematopoiesis
2000
Erythrocyte sedimentation rate, C‐reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti–tumor necrosis factor treatment in ankylosing spondylitis
2009
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Transforming growth factor-β: pleiotropic role in the regulation of hematopoiesis
2000
Psoriasis Pathogenesis and Treatment
2019 Standout
The Psychological Meaning of Words: LIWC and Computerized Text Analysis Methods
2009 Standout
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
2007
Nonpharmacologic Therapies for Acute and Chronic Low Back Pain: A Review of the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline
2007 Standout
Role of PTEN/PI3K pathway in endothelial cells
2007 StandoutNobel
Chapter 4European guidelinesfor the management of chronicnonspecific low back pain
2006 Standout
Effects of written emotional disclosure on health outcomes in patients with ankylosing spondylitis
2007
Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes.
2005
Endothelial/Pericyte Interactions
2005 Standout
Telomerase activation: one step on the road to cancer?
1999 StandoutNobel
Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis.
2007
Health-related quality of life in ankylosing spondylitis: A survey of 175 patients
1999
Angiogenesis Ischemic and Neoplastic Disorders
2003 StandoutNobel
Effectiveness of massage therapy for subacute low-back pain: a randomized controlled trial.
2000
Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial.
2004
Altered Expression of the Retinoblastoma Tumor-Suppressor Gene in Leukemic Cell Lines Inhibits Induction of Differentiation But Not G1-Accumulation
1997
TNF‐mediated inflammatory disease
2007 Standout
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
The Cochrane review of physiotherapy interventions for ankylosing spondylitis.
2005
Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease
2011 Standout
Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice
1995
Works of T Jenkinson being referenced
ANKYLOSING SPONDYLITIS: THE CORRELATION BETWEEN A NEW METROLOGY SCORE AND RADIOLOGY
1995
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
1994
Effect of transforming growth factor-beta 1 on proliferation and induction of hemoglobin accumulation in K-562 cells
1989
A reappraisal of steroid-induced osteoporosis.
1994
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.
1994 Standout
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.
1994 Standout